 |
|
Waiting for the changes after the adoption of steatotic liver disease
Eileen L. Yoon, Dae Won Jun
Clin Mol Hepatol. 2023;29(4):844-850. Published online 2023 Sep 6 DOI: https://doi.org/10.3350/cmh.2023.0291
|
|
Citations to this article as recorded by
 Changing from NAFLD to MASLD: Similar prognosis of unresectable extrahepatic gastrointestinal cancer under chemotherapy between NAFLD and MASLD
Hiroyuki Suzuki, Toshimitsu Tanaka, Shotaro Yamaguchi, Keisuke Miwa, Takumi Kawaguchi
Journal of Hepatology.2024; 80(4): e150. CrossRef Three-Step Algorithm for Screening High-Risk Group of Metabolic Dysfunction-Associated Steatotic Liver Disease in General Population
Joo Hyun Oh, Dae Won Jun
Gut and Liver.2024; 18(2): 197. CrossRef Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD
Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi
Clinical and Molecular Hepatology.2024; 30(2): 263. CrossRef Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences
Joo Hyun Oh, Dae Won Jun
Clinical and Molecular Hepatology.2024; 30(2): 168. CrossRef Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi
Clinical and Molecular Hepatology.2024; 30(2): 266. CrossRef Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study
Michihiro Iwaki, Hideki Fujii, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Miwa Kawanaka, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Tsubasa Tsutsumi, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Na
Clinical and Molecular Hepatology.2024; 30(2): 225. CrossRef Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities
Muhammed Mubarak
World Journal of Gastrointestinal Pathophysiology.2024;[Epub] CrossRef Diagnostic performances of Fibrosis‐4 index and nonalcoholic fatty liver disease fibrosis score in metabolic dysfunction‐associated steatotic liver disease in Asian primary care clinics
Huiyul Park, Mimi Kim, Hye‐Lin Kim, Seon Cho, Eileen L. Yoon, Dae Won Jun
Hepatology Research.2024;[Epub] CrossRef Metabolic dysfunction-associated steatotic liver disease: Evolution of the final terminology
Piero Portincasa, Gyorgy Baffy
European Journal of Internal Medicine.2024; 124: 35. CrossRef Revisiting the steatosis‐associated fibrosis estimator score in young Asian subjects with steatotic liver disease and consideration for population variability
Jiwon Yang, Won‐Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Jonggi Choi
Journal of Gastroenterology and Hepatology.2024; 39(10): 2112. CrossRef Barriers to care linkage and educational impact on unnecessary MASLD referrals
Jun-Hyuk Lee, Eileen Laurel Yoon, Ju Hyun Oh, Kyunam Kim, Sang Bong Ahn, Dae Won Jun
Frontiers in Medicine.2024;[Epub] CrossRef A New Korean Nomenclature for Steatotic Liver Disease
The Korean Journal of Gastroenterology.2024; 84(1): 1. CrossRef A New Korean Nomenclature for Steatotic Liver Disease
The Korean Journal of Medicine.2024; 99(4): 189. CrossRef Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study
Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung
Cancers.2024; 16(18): 3161. CrossRef A New Korean Nomenclature for Steatotic Liver Disease
Gut and Liver.2024; 18(5): 924. CrossRef Reply to “Is liver fibrosis more advanced in MetALD than in MASLD?”
Joo Hyun Oh, Dae Won Jun
Journal of Hepatology.2024;[Epub] CrossRef A new Korean nomenclature for steatotic liver disease: Nonalcoholic Fatty Liver Disease (NAFLD) Nomenclature Revision Consensus Task Force on behalf of the Korean Association for the Study of the Liver (KASL)
Clinical and Molecular Hepatology.2024; 30(Suppl): S214. CrossRef From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
Li Chen
World Journal of Hepatology.2023; 15(12): 1253. CrossRef Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
Kuo Chao Yew, Sunny H. Wong, Vincent Wai-Sun Wong, Hazel H. Oon
Clinical and Molecular Hepatology.2023; 30(1): 118. CrossRef Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
Eileen L. Yoon, Dae Won Jun
Clinical and Molecular Hepatology.2023; 30(1): 126. CrossRef Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD
Shuhei Fukunaga, Michita Mukasa, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi
Clinical and Molecular Hepatology.2023; 30(1): 121. CrossRef
|